BLASUBCUTANEOUSINJECTABLE
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYMPAVZI (marstacimab-hncq) is a monoclonal antibody approved in October 2024 by Pfizer for subcutaneous injection. The drug mechanism of action and specific indications are not yet publicly detailed in available data. Patient eligibility and therapeutic target will become clearer as clinical labeling and marketing materials emerge post-launch.
Growth
Early-stage growth product with moderate competitive pressure (30/100) suggests opportunity to build market share, likely requiring expanded commercial and medical affairs teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
Started Oct 2025
50 enrolled
Hemophilia A or B
Why This Matters for Your Career
Worked on HYMPAVZI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.